1. Home >
  2. M&A >
  3. Going Private >
  4. United States >
  5. Massachusetts >
  6. La Jolla Pharmaceutical Acquires Tetraphase Pharmaceuticals

M&A Deal Summary

La Jolla Pharmaceutical Acquires Tetraphase Pharmaceuticals

On June 24, 2020, La Jolla Pharmaceutical acquired life science company Tetraphase Pharmaceuticals for 43M USD

Acquisition Highlights
  • This is La Jolla Pharmaceutical’s 1st transaction in the Life Science sector.
  • This is La Jolla Pharmaceutical’s largest (disclosed) transaction.
  • This is La Jolla Pharmaceutical’s 2nd transaction in the United States.
  • This is La Jolla Pharmaceutical’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-06-24
Target Tetraphase Pharmaceuticals
Sector Life Science
Buyer(s) La Jolla Pharmaceutical
Deal Type Going Private
Deal Value 43M USD
Advisor(s) Janney Montgomery Scott (Financial)
Wilmer Cutler Pickering Hale and Dorr (Legal)

Target

Tetraphase Pharmaceuticals

Watertown, Massachusetts, United States
Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) infections. Tetraphase Pharmaceuticals was founded in 2006 and is based in Watertown, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

La Jolla Pharmaceutical

Waltham, Massachusetts, United States
Category Company
Founded 1989
Sector Life Science
Revenue 76M USD (2021)
DESCRIPTION

La Jolla Pharmaceutical is a biotechnology company involved in the development of therapeutics for lupus nephritis and other autoimmune diseases. La Jolla Pharmaceutical was founded in 1989 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 1 of 1
Type: Going Private M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2020 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-19 Solana Therapeutics

San Diego, California, United States

Solana Therapeutics, Inc. is a developer and manufacturer of drug GCS-100.

Buy -
Mergr

Solution for

Product

Company

Legal